+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Behcet Disease Drug Market - Global Forecast to 2030- Product Image
Behcet Disease Drug Market - Global Forecast to 2030- Product Image
Sale

Behcet Disease Drug Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6013868
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Behcet Disease Drug Market grew from USD 522.56 million in 2024 to USD 543.43 million in 2025. It is expected to continue growing at a CAGR of 3.96%, reaching USD 659.74 million by 2030.

Behçet disease presents a formidable challenge to clinicians and patients alike, given its multisystem inflammatory nature and unpredictable flare patterns. Historically, therapeutic strategies relied heavily on broad immunosuppression, leaving gaps in efficacy and tolerability. Recent advances in drug development showcase a shift toward targeted therapies that modulate specific inflammatory pathways, offering new hope for disease control and improved quality of life. This section introduces the current landscape, highlighting unmet clinical needs, the rationale for precision medicine approaches, and the imperative for stakeholders to stay abreast of evolving therapeutic options. By understanding the trajectory of innovation, decision-makers can optimize treatment algorithms and drive better patient outcomes in the face of a complex, systemic vasculitis.

Transformative Shifts Reshaping Behçet Disease Treatment Paradigms

Over the past decade, the Behçet disease landscape has experienced transformative shifts driven by breakthroughs in biologic engineering, enhancements in small molecule design, and the integration of real-world evidence into regulatory pathways. Advances in cytokine profiling have illuminated the pivotal role of interleukin-17 and tumor necrosis factor in disease pathogenesis, prompting the rapid emergence of monoclonal antibodies and receptor antagonists tailored to these targets. Concurrently, improvements in drug delivery-spanning subcutaneous self-administration devices and long-acting injectable formulations-have reshaped patient adherence and convenience. Moreover, the incorporation of machine learning algorithms into clinical trial design has accelerated patient stratification, enabling more efficient assessment of safety and efficacy. These collective innovations are redefining standards of care, elevating expectations for remission rates, and setting new benchmarks for tolerability and long-term management.

Cumulative Impact of United States Tariffs in 2025 on Market Dynamics

The United States’ 2025 tariff adjustments on pharmaceutical imports are poised to exert significant cumulative impacts throughout the Behçet disease drug market. Increased duties on active pharmaceutical ingredients and finished formulations may elevate manufacturing costs for both biologic agents and small molecules, ultimately translating into higher list prices. Suppliers are exploring regional manufacturing hubs and vertical integration strategies to mitigate tariff burdens, yet logistical complexities and regulatory harmonization challenges persist. In parallel, patient assistance programs and public-private partnerships are being reconfigured to offset out-of-pocket burdens, preserving access for vulnerable populations. Stakeholders must anticipate potential shifts in payer reimbursement policies, monitor pricing benchmarks across key markets, and adapt contracting approaches to maintain competitive positioning in a dynamically evolving cost environment.

Key Segmentation Insights Across Therapeutic, Delivery, and Patient Dimensions

Analyzing market segmentation offers a nuanced view of where therapeutic opportunities and competitive pressures converge. Looking at drug type, the distinction between biologics and small molecules underscores the differential impact of manufacturing complexity, regulatory pathways, and cost structures on product adoption. Route of administration further refines this view, as the convenience and patient preference associated with oral therapies contrast sharply with the controlled delivery of intravenous infusions and the self-injection appeal of subcutaneous regimens. Within drug classes, antimetabolites, colchicine derivatives, corticosteroids, and TNF inhibitors each bring unique efficacy profiles and safety considerations, dictating their role in first-line versus refractory disease management. Therapeutic application segmentation reveals unmet needs across central nervous system manifestations, genital lesions, ocular lesions-subdivided into retinal vasculitis and uveitis-oral lesions, and vascular disease, highlighting areas for targeted clinical trials and label expansions. Dosage form analysis-from capsules and tablets to injections, including pre-filled syringes and vials, and suspensions-illustrates how formulation innovation can enhance bioavailability and patient adherence. Patient type stratification, encompassing adult, geriatric, and pediatric cohorts, emphasizes the necessity of age-appropriate dosing strategies and safety monitoring. End user insights, spanning clinics, hospitals-both general and specialty clinics-and retail pharmacies, illuminate where distribution efficiencies and stakeholder education efforts can maximize market penetration. Distribution channel dynamics, whether through hospital pharmacies, online pharmacies, or retail outlets, inform logistics and patient access initiatives. Application in other diseases, such as Crohn’s disease, psoriasis, and rheumatoid arthritis, demonstrates the potential for off-label adoption and lifecycle management strategies. Finally, development stage segmentation-approved products, clinical trials categorized into Phase I, Phase II, and Phase III, and off-label use-offers a real-time outlook on pipeline maturity and emergent competitive threats.

Key Regional Insights Influencing Market Access and Growth

Regional nuances are critical in charting growth strategies and resource allocation. In the Americas, the convergence of robust reimbursement frameworks with accelerated regulatory approvals fosters a fertile environment for the launch of novel biologics and small molecules, yet cost containment pressures and managed care restrictions influence pricing negotiations. Within Europe, Middle East & Africa, heterogeneity in healthcare infrastructure and public-sector funding models underscores the need for tailored market access approaches, with particular emphasis on health technology assessments and outcome-based contracting. In Asia-Pacific, dynamic markets range from highly regulated, high-income economies prioritizing innovation to emerging markets with evolving regulatory oversight and growing demands for affordable generics and biosimilars. Strategic investments in local manufacturing and early engagement with regional health authorities are proving indispensable for navigating diverse policy landscapes and accelerating product uptake.

Key Company Strategies and Competitive Dynamics

A constellation of global and specialty players is shaping the Behçet disease drug arena. Pharmaceutical leaders such as AbbVie Inc. and AstraZeneca plc are leveraging their biologics expertise to advance pipeline candidates targeting interleukin and TNF pathways, while Allergan plc and Amgen Inc. capitalize on small molecule platforms to diversify treatment modalities. Bayer AG and Biogen Inc. are forging partnerships to explore novel immunomodulatory agents, complementing established portfolios from Bristol-Myers Squibb Company and Celgene Corporation. Eli Lilly and Company is integrating predictive analytics into clinical development, whereas Gilead Sciences, Inc. pursues combination strategies to amplify efficacy. GlaxoSmithKline plc and Johnson & Johnson are optimizing global manufacturing networks to mitigate supply chain risks, and Merck & Co., Inc. alongside Novartis AG focus on life cycle management, including label expansions into ocular and vascular applications. Pfizer Inc. and Roche Holding AG are investing heavily in next-generation delivery systems, while Sanofi S.A. and Takeda Pharmaceutical Company Limited explore adaptive licensing to accelerate access. Teva Pharmaceutical Industries Ltd. continues to drive affordability through biosimilar development, underscoring the competitive complexity and innovation-driven nature of the current landscape.

Actionable Recommendations for Industry Leadership

To thrive in this rapidly evolving environment, industry leaders should adopt a multifaceted approach. First, aligning R&D portfolios with precision medicine trends-by prioritizing targets validated through biomarker-driven studies-can accelerate regulatory success and clinical adoption. Second, investing in next-generation delivery systems that enhance patient adherence and enable home administration will differentiate offerings and support premium pricing models. Third, forging strategic alliances with patient advocacy groups and payers to co-create value frameworks can streamline access and reduce time to reimbursement. Fourth, establishing regional centers of excellence for manufacturing and regulatory affairs will mitigate trade-related cost pressures and expedite market entry. Finally, harnessing real-world evidence and digital health platforms for post-market surveillance and outcome validation will bolster payer confidence and inform iterative product enhancements.

Conclusion and Strategic Imperatives

The Behçet disease therapeutic landscape stands at an inflection point where precision targeting, innovative delivery, and collaborative market access models converge to redefine standards of care. Stakeholders who integrate advanced segmentation insights, anticipate regulatory and tariff shifts, and engage in strategic partnerships will be best positioned to deliver transformative patient outcomes while sustaining commercial success. By maintaining agility in development strategies and deepening regional expertise, organizations can navigate complexity and drive enduring value in this specialized immunology segment.

Market Segmentation & Coverage

This research report categorizes the Behcet Disease Drug Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Biologics
  • Small Molecules
  • Intravenous
  • Oral
  • Subcutaneous
  • Antimetabolites
  • Colchicine Derivatives
  • Corticosteroids
  • TNF Inhibitors
  • Central Nervous System Manifestations
  • Genital Lesions
  • Ocular Lesions
    • Retinal Vasculitis
    • Uveitis
  • Oral Lesions
  • Vascular Disease
  • Capsules
  • Injections
    • Pre-filled Syringes
    • Vials
  • Suspensions
  • Tablets
  • Adult
  • Geriatric
  • Pediatric
  • Clinics
  • Hospitals
    • General Hospitals
    • Specialty Clinics
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Crohn’s Disease
  • Psoriasis
  • Rheumatoid Arthritis
  • Approved
  • Clinical Trials
    • Phase I
    • Phase II
    • Phase III
  • Off-Label Use

This research report categorizes the Behcet Disease Drug Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Behcet Disease Drug Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Behcet Disease Drug Market, by Drug Type
8.1. Introduction
8.2. Biologics
8.3. Small Molecules
9. Behcet Disease Drug Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Behcet Disease Drug Market, by Drug Class
10.1. Introduction
10.2. Antimetabolites
10.3. Colchicine Derivatives
10.4. Corticosteroids
10.5. TNF Inhibitors
11. Behcet Disease Drug Market, by Therapeutic Application
11.1. Introduction
11.2. Central Nervous System Manifestations
11.3. Genital Lesions
11.4. Ocular Lesions
11.4.1. Retinal Vasculitis
11.4.2. Uveitis
11.5. Oral Lesions
11.6. Vascular Disease
12. Behcet Disease Drug Market, by Dosage Form
12.1. Introduction
12.2. Capsules
12.3. Injections
12.3.1. Pre-filled Syringes
12.3.2. Vials
12.4. Suspensions
12.5. Tablets
13. Behcet Disease Drug Market, by Patient Type
13.1. Introduction
13.2. Adult
13.3. Geriatric
13.4. Pediatric
14. Behcet Disease Drug Market, by End User
14.1. Introduction
14.2. Clinics
14.3. Hospitals
14.3.1. General Hospitals
14.3.2. Specialty Clinics
14.4. Retail Pharmacies
15. Behcet Disease Drug Market, by Distribution Channel
15.1. Introduction
15.2. Hospital Pharmacies
15.3. Online Pharmacies
15.4. Retail Pharmacies
16. Behcet Disease Drug Market, by Application In Other Diseases
16.1. Introduction
16.2. Crohn’s Disease
16.3. Psoriasis
16.4. Rheumatoid Arthritis
17. Behcet Disease Drug Market, by Development Stage
17.1. Introduction
17.2. Approved
17.3. Clinical Trials
17.3.1. Phase I
17.3.2. Phase II
17.3.3. Phase III
17.4. Off-Label Use
18. Americas Behcet Disease Drug Market
18.1. Introduction
18.2. Argentina
18.3. Brazil
18.4. Canada
18.5. Mexico
18.6. United States
19. Asia-Pacific Behcet Disease Drug Market
19.1. Introduction
19.2. Australia
19.3. China
19.4. India
19.5. Indonesia
19.6. Japan
19.7. Malaysia
19.8. Philippines
19.9. Singapore
19.10. South Korea
19.11. Taiwan
19.12. Thailand
19.13. Vietnam
20. Europe, Middle East & Africa Behcet Disease Drug Market
20.1. Introduction
20.2. Denmark
20.3. Egypt
20.4. Finland
20.5. France
20.6. Germany
20.7. Israel
20.8. Italy
20.9. Netherlands
20.10. Nigeria
20.11. Norway
20.12. Poland
20.13. Qatar
20.14. Russia
20.15. Saudi Arabia
20.16. South Africa
20.17. Spain
20.18. Sweden
20.19. Switzerland
20.20. Turkey
20.21. United Arab Emirates
20.22. United Kingdom
21. Competitive Landscape
21.1. Market Share Analysis, 2024
21.2. FPNV Positioning Matrix, 2024
21.3. Competitive Analysis
21.3.1. AbbVie Inc.
21.3.2. Allergan plc
21.3.3. Amgen Inc.
21.3.4. AstraZeneca plc
21.3.5. Bayer AG
21.3.6. Biogen Inc.
21.3.7. Bristol-Myers Squibb Company
21.3.8. Celgene Corporation
21.3.9. Eli Lilly and Company
21.3.10. Gilead Sciences, Inc.
21.3.11. GlaxoSmithKline plc
21.3.12. Johnson & Johnson
21.3.13. Merck & Co., Inc.
21.3.14. Novartis AG
21.3.15. Pfizer Inc.
21.3.16. Roche Holding AG
21.3.17. Sanofi S.A.
21.3.18. Takeda Pharmaceutical Company Limited
21.3.19. Teva Pharmaceutical Industries Ltd.
22. ResearchAI
23. ResearchStatistics
24. ResearchContacts
25. ResearchArticles
26. Appendix
List of Figures
FIGURE 1. BEHCET DISEASE DRUG MARKET MULTI-CURRENCY
FIGURE 2. BEHCET DISEASE DRUG MARKET MULTI-LANGUAGE
FIGURE 3. BEHCET DISEASE DRUG MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 22. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2024 VS 2030 (%)
FIGURE 24. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 26. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 30. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 34. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 35. BEHCET DISEASE DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 36. BEHCET DISEASE DRUG MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BEHCET DISEASE DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY COLCHICINE DERIVATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY CENTRAL NERVOUS SYSTEM MANIFESTATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY GENITAL LESIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY RETINAL VASCULITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY UVEITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY ORAL LESIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY VASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY VIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY CROHN’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY APPROVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BEHCET DISEASE DRUG MARKET SIZE, BY OFF-LABEL USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 105. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 106. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 110. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 111. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 112. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 113. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 115. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2018-2030 (USD MILLION)
TABLE 117. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 118. CANADA BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 119. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 120. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 124. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 125. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 126. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 127. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 129. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2018-2030 (USD MILLION)
TABLE 131. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 132. MEXICO BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES BEHCET DISEASE DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 148. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 149. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 151. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 154. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 155. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 156. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 158. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2018-2030 (USD MILLION)
TABLE 160. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 161. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 162. ASIA-PACIFIC BEHCET DISEASE DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 163. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 164. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 166. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 168. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 169. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 170. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 171. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 173. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2018-2030 (USD MILLION)
TABLE 175. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 176. AUSTRALIA BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 177. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 178. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 180. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 182. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 183. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 184. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 185. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 187. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2018-2030 (USD MILLION)
TABLE 189. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 190. CHINA BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 191. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 192. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 194. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 196. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 197. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 198. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 199. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 201. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2018-2030 (USD MILLION)
TABLE 203. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 204. INDIA BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 205. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 206. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 208. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 209. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 210. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 211. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 212. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 213. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 215. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2018-2030 (USD MILLION)
TABLE 217. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 218. INDONESIA BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 219. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 220. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 222. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 223. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 224. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 225. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 226. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 227. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 229. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2018-2030 (USD MILLION)
TABLE 231. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 232. JAPAN BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 233. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 234. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 236. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 237. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 238. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 239. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 240. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 241. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 243. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2018-2030 (USD MILLION)
TABLE 245. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 246. MALAYSIA BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 247. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 248. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 249. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 250. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 251. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 252. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 253. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 254. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 255. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 257. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2018-2030 (USD MILLION)
TABLE 259. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 260. PHILIPPINES BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 261. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 262. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 264. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 265. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 266. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 267. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 268. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 269. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 271. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2018-2030 (USD MILLION)
TABLE 273. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 274. SINGAPORE BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 276. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 278. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 279. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 280. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 281. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 282. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 283. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 285. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 286. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2018-2030 (USD MILLION)
TABLE 287. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 288. SOUTH KOREA BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 289. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 290. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 292. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 293. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 294. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 295. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 296. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 297. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 299. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 300. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2018-2030 (USD MILLION)
TABLE 301. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 302. TAIWAN BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 303. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 304. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 305. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 306. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 307. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 308. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 309. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 310. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 311. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 312. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 313. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 314. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2018-2030 (USD MILLION)
TABLE 315. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 316. THAILAND BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 317. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 318. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 319. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 320. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 321. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 322. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 323. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 324. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 325. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 326. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 327. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 328. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY APPLICATION IN OTHER DISEASES, 2018-2030 (USD MILLION)
TABLE 329. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 330. VIETNAM BEHCET DISEASE DRUG MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 331. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 332. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 333. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 334. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 335. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY OCULAR LESIONS, 2018-2030 (USD MILLION)
TABLE 336. EUROPE, MIDDLE EAST & AFRICA BEHCET DISEASE DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 337. EUROPE,

Companies Mentioned

  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Behcet's Disease - Pipeline Insight, 2025 - Product Image

Behcet's Disease - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Behcet Disease Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Behcet Disease Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 82 Pages
  • Global
From
Behçet Disease - Pipeline Insight, 2025 - Product Image

Behçet Disease - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Anti-Rheumatics Market by Drug Class (Corticosteroids, Disease Modifying Anti-rheumatics Drugs, Nonsteroidal Anti-inflammatory Drugs), Route Of Administration (Injectable, Oral, Topical), Type, Disease Type, Distribution Channel - Global Forecast 2025-2030 - Product Image

Anti-Rheumatics Market by Drug Class (Corticosteroids, Disease Modifying Anti-rheumatics Drugs, Nonsteroidal Anti-inflammatory Drugs), Route Of Administration (Injectable, Oral, Topical), Type, Disease Type, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Ulcerative Colitis Market - Global Forecast to 2030 - Product Image

Ulcerative Colitis Market - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global, United States Global, United States
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.